VIDEO

SNTX-2643 Phase 1a results discussion with Dr Jacob Hooker and Dr Cole Brown

Jacob Hooker, Ph.D, Sensorium Co-founder and CEO, and Cole Brown, M.D., Sensorium Chief Medical Officer, discuss the results of SNTX-2643's Phase 1a trial, and put them in the context of the company's mission, method, and future. For complete details, including important information about forward-looking statements, see our news announcement.

What we found
SNTX-2643 was generally well tolerated and demonstrated predictable pharmacokinetics with no clinically significant food effect in healthy participants. In an exploratory target-engagement analysis, a single 3 mg dose attenuated the brain’s response to an experimentally induced psychological stressor at both two and 24 hours with concurrent responses seen in autonomic measures at both time points. After a single dose, pharmacodynamic activity remained evident at 24 hours as plasma exposure declines, suggesting potential durability beyond peak systemic exposure.

These are early findings in 63 healthy volunteers, from exploratory analyses that were not prespecified for hypothesis testing, and they do not establish clinical efficacy.

Overview of SNTX-2643 Phase 1a results

In a brief overview, Jacob and Cole share the first exploratory Phase 1a results for SNTX-2643 in healthy volunteers, including measures of brain activity and heart rate, and explain what these early findings do and do not tell us yet.

What we learned in Phase 1a

Jacob and Cole introduce the first exploratory Phase 1a findings for SNTX-2643, including tolerability, brain activity, and reduced heart rate and increased heart-rate variability, a pattern consistent with increased parasympathetic tone.

Anxiety disorders are debilitating

Cole reflects on how anxiety disorders keep people from time with family, friends, and the events they enjoy, and on the unmet need that remains.

Effects at two and 24 hours

Cole explains why exploratory changes seen at two hours, and effects that remained evident at 24 hours as drug levels in the blood declined, caught the team’s attention, and what further studies will need to show.

Starting and ending with humans

Jacob describes how a computational look at patterns in the human use of natural products led to SNTX-2643, an investigational, state-selective serotonin transporter modulator.

The throughline

Jacob traces the thread running through Sensorium’s work, from human knowledge to animal models to molecules, and how each step has revealed something new about how nature interacts with biology.

Future of medicine

Jacob makes the case that medicines inspired by nature can be pursued with scientific rigor, pairing mechanistic biology with formal testing to look for new therapies.

Sensorium's future

Jacob looks ahead to what the first signals from patients could tell us, both for people with anxiety disorders and for Sensorium’s approach to discovery.

These materials reflect data as of the publication date, and have not been independently peer reviewed or updated since.

SNTX-2643 is investigational. It has not been approved by the U.S. Food and Drug Administration or any other regulatory authority, and its safety and efficacy have not been established. These materials may contain forward-looking statements subject to the risks of drug development, are not an offer to sell or a solicitation to buy securities, and may not be reproduced or redistributed without Sensorium's written consent.

© 2026 Sensorium Therapeutics, Inc.

Sensorium Therapeutics is a clinical stage biotechnology company developing brain and mental health treatments that are derived from nature, mechanistically driven, clinically precise, and designed to help people thrive. Its proprietary SensAI™ platform integrates artificial intelligence, chemistry, and neuroscience to mine more than 50 million curated relationships across biology, pharmacology, clinical outcomes, and human experience to unlock broader and derisked starting points for CNS drug discovery. SensAI has produced three differentiated programs in under three years—led by SENS-01, a first-in-class compound under investigation for the treatment of anxiety disorders—and built a robust IP estate extending into the 2040s.

SNTX-2643 discussion

SNTX-2643 Phase 1a results discussion with Dr Jacob Hooker and Dr Cole Brown

Overview of SNTX-2643 Phase 1a results

What we learned in Phase 1a

Anxiety disorders are debilitating

Effects at two and 24 hours

Starting and ending with humans

The throughline

Future of medicine

Sensorium's future

‍News

Team

‍Careers

‍Contact